Perkmann Perkmann

Dr. Perkmann Perkmann

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2023 in Trials
Verified
Journal Article
Open access
PDF file
FZFrancesco Zaraca
Francesco Zaraca
AKAndreas Kirschbaum
Andreas Kirschbaum
MPMarco Damiano Pipitone
Marco Damiano Pipitone
Luca BertolacciniLuca Bertolaccini
Luca Bertolaccini
TGThe PATCHES study group
The PATCHES study group
PUPaula Ugalde
Paula Ugalde
Introduction: Pulmonary segmentectomy, when combined with hilar and mediastinal lymphadenectomy, is currently considered the gold standard treatment for early-stage lung tumors (NSCLC) smaller than 2 cm in diameter. The preoperative planning for segmentectomies usually includes a contrast-enhanced CT with 2D reconstructions (axial, coronary, and sagittal). Recent technological advances allow 3D (volume rendering) reconstructions of preoperative CT scans, intended to improve the surgeon’s understanding of the segmental anatomy. The study aims to investigate the added value of 3D reconstruction in enhancing the surgeon’s understanding of anatomical structures, thus facilitating surgical planning and improving oncological outcomes. Methods and analysis: This is a prospective, randomized, controlled study. Patients will be randomized into two groups: 1. Group 2D: the preoperative workup for these patients will consist of a contrast-enhanced chest CT with two-dimensional (2D) reconstructions (axial, coronary, and sagittal); 2. Group 3D: the preoperative workup for these patients will consist of a contrast-enhanced chest CT with two-dimensional (2D) reconstructions (axial, coronary, and sagittal) and a 3D reconstruction (volume rendering) of the same chest CT employing dedicated software. The primary endpoints will be negative margin (R0) resection rate, resection margin (staple line-to-tumor distance), and thoracotomy conversions. We will use Fisher’s exact test for binary outcomes and Mann–Whitney U test for continuous outcomes. For subgroup analyses, we will use regression. Multivariable analyses will be based on logistic regression for binary outcomes and linear regression for continuous outcomes. Ethics and dissemination: The protocol and the model informed consent forms have been reviewed and approved by the ethics committee (N.: 1–2023) concerning scientific content and compliance with applicable research and human subject regulations. A Subcommittee on Publications was established to review all publications and report its recommendations to the steering committee. The anonymized participant-level dataset and statistical code for generating the results will not be publicly available. Trial registration: The protocol was registered at ClinicalTrials.gov (ID: NCT05716815; Prospective rAndomized sTudy efficaCy tHree-dimensional rEconstructions Segmentectomy - Full-Text View - ClinicalTrials.gov). Jan 19, 2023.

2 December 2013 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
CSCarlo Stringari
Carlo Stringari
PPPerkmann Perkmann
Perkmann Perkmann
FZFrancesco Zaraca
Francesco Zaraca

1 December 2017 in ASVIDE
Verified
Journal Article
Closed access
FZFrancesco Zaraca
Francesco Zaraca
MVMaurizio Vaccarili
Maurizio Vaccarili
GZGino Zaccagna
Gino Zaccagna
PMPio Maniscalco
Pio Maniscalco
GDGiampiero Dolci
Giampiero Dolci
RCRoberto Crisci
Roberto Crisci

1 April 2018 in Journal of Visualized Surgery
Verified
Journal Article
Closed access
PDF file
RCRoberto Crisci
Roberto Crisci
PPPerkmann Perkmann
Perkmann Perkmann
FZFrancesco Zaraca
Francesco Zaraca
VATS and RATS lobectomy up to date: clinical and experimental evidences

25 September 2026 in Updates in Surgery
Verified
Journal Article
Open access
PDF file
GZGiovanni Zambello
Giovanni Zambello
ABAlberto Busetto
Alberto Busetto
RARiccardo Amatucci
Riccardo Amatucci
MPMarco Damiano Pipitone
Marco Damiano Pipitone
GCGiovanni Coppi
Giovanni Coppi
FZFrancesco Zaraca
Francesco Zaraca
Advanced non-small cell lung cancer (NSCLC) with thoracic aortic invasion (T4Ao) is a life-threatening condition and represents a major therapeutic challenge. Radiotherapy (RT) is often recommended for local control or palliation; however, it carries a substantial risk of vascular complications, including aortic rupture, thrombosis and pseudoaneurysm formation. Thoracic endovascular aortic repair (TEVAR) provides mechanical reinforcement of the aortic wall, potentially mitigating these risks and enabling safer administration of high-dose RT. This technical note describes our experience with prophylactic TEVAR (p-TEVAR) performed prior to RT. Three patients with cT4Ao-NSCLC completed the procedure and subsequent treatment without procedure-related vascular complications, achieving partial tumor response in two patients. Follow-up ranged from 6 to 10 months after radiotherapy, with no evidence of endoleak, graft migration, thrombosis, pseudoaneurysm, or aortic rupture. p-TEVAR may represent a feasible adjunct to radiotherapy or chemoradiotherapy in selected patients with advanced thoracic malignancies involving the aorta. This study highlights the feasibility of endovascular reinforcement and the importance of multidisciplinary decision-making.

2 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGiovanni Coppi
Giovanni Coppi
LMLuiz Felippe Milazzo
Luiz Felippe Milazzo
MPMarco Damiano Pipitone
Marco Damiano Pipitone
GZGiovanni Zambello
Giovanni Zambello
FZFrancesco Zaraca
Francesco Zaraca
PPPerkmann Perkmann
Perkmann Perkmann
Background: Current guidelines recommend delaying extracranial carotid revascularization for at least 6–7 days after intravenous thrombolysis (IVT). However, evidence remains inconclusive, and patients with minimal or no brain lesions may benefit from earlier intervention. Objective: This scoping review evaluates outcomes of carotid revascularization performed within six days of IVT in patients with small strokes or no imaging-detected lesions. Design: We searched Medline, EMBASE, and Cochrane CENTRAL for studies published between 2005 and 2025 reporting carotid revascularization after IVT. Primary outcomes included perioperative ischemic stroke, symptomatic intracranial hemorrhage (sICH), asymptomatic intracranial bleeding (aICB), and wound complications. Data on timing, imaging findings (CT/MRI), and stroke severity (NIHSS or modified Rankin scale) were extracted. The review followed PRISMA-ScR guidelines. Results: Seventeen studies (1459 patients) were included; 97.6% underwent carotid endarterectomy (CEA) and 2.4% carotid artery stenting (CAS). Data for procedures within six days post-IVT were available for 402 patients, with some treated within 24–72 h. Mean NIHSS at admission was 10.2 ± 2.8. Brain lesion characterization was poor and only used as an exclusion criterion. Thirty-day ischemic stroke incidence was 2.5%, while combined sICH/aICB was 4.0%, with symptomatic cases at 2.5%. Most hemorrhages occurred in patients operated within 48–72 h from IVT and in patients with higher NIHSS. CAS carried higher sICH risk than CEA (8.6% vs. 1.9%). Overall mortality was 1.1%; wound complications occurred in 3.7%. Conclusions: The available literature provides limited characterization of brain lesion extent. Neurological complications after CEA are rare, mainly limited to patients operated within 48–72 h from IVT. Further research is needed to optimize treatment in this patient group, although delaying CEA only to 48–72 h seems reasonable in case of low NIHSS.